Avinger Inc (AVGR): John D. Simpson , Sr. VP, Sales & Marketing of Avinger Inc sold 32,500 shares on Jul 20, 2016. The Insider selling transaction was reported by the company on Jul 22, 2016 to the Securities and Exchange Commission. The shares were sold at $6.28 per share for a total value of $204,025.25 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 10, 2016, Himanshu Patel (CTO) sold 10,000 shares at $13.40 per share price.On Apr 19, 2016, John B Ph D Md Simpson (Executive Chairman) sold 75,111 shares at $13.11 per share price.Also, On Mar 15, 2016, Matthew Ferguson (CFO) purchased 1,500 shares at $11.40 per share price.On Feb 4, 2015, James Cullen (director) sold 2,307 shares at $13.00 per share price.
Shares of Avinger Inc (AVGR) ended Wednesday, Jul 20, 2016 session in red amid volatile trading. The shares closed down -0.07 points or -1.10% at $6.3 with 2,30,326 shares getting traded. Post opening the session at $6.35, the shares hit an intraday low of $6.23 and an intraday high of $6.37 and the price vacillated in this range throughout the day. The company has a market cap of $80 M and the number of outstanding shares has been calculated to be 1,26,93,485 shares. The 52-week high of Avinger Inc is $25.11 and the 52-week low is $6.161.
Avinger Inc. is a commercial-stage medical device company. The Company designs manufactures and sells image-guided catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses to introduce products based on its lumivascular platform which is an intravascular image-guided system. The Company manufactures and sells a suite of products in the United States and select European markets. The Company’s products include Lightbox imaging console as well as Wildcat Kittycat and the Ocelot family of catheters which are designed to allow physicians to penetrate a total blockage in an artery known as a chronic total occlusion (CTO). The Company’s lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment.